Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W P Sheffield

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Current Drug Targets. Cardiovascular & Haematological Disorders|May 29, 2003
Modification of clearance of therapeutic and potentially therapeutic proteinsW P Sheffield
Thrombosis Research|August 1, 1994
Amino acid substitutions of the P2 residue of human antithrombin that either enhance or impair functionW P Sheffield, M A Blajchman
FEBS Letters|February 14, 1994
Site-directed mutagenesis of the P2 residue of human antithrombinW P Sheffield, M A Blajchman
FEBS Letters|May 29, 1995
Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpinW P Sheffield, M A Blajchman
Vox Sanguinis|July 17, 2015
Stability of coagulation protein activities in single units or pools of cryoprecipitate during storage at 20-24°C for up to 24 hW P Sheffield, V Bhakta, C Jenkins
The Journal of Biological Chemistry|December 5, 1989
Regulation of ornithine aminotransferase in retinoblastomasR J Fagan, W P Sheffield, R Rozen
Biochemical and Biophysical Research Communications|January 14, 1986
Expression in Escherichia coli of functional precursor to the rat liver mitochondrial enzyme, ornithine carbamyl transferase. Precursor import and processing in vitroW P Sheffield, M Nguyen, G C Shore
Vox Sanguinis|April 7, 2017
Bacteria can proliferate in thawed cryoprecipitate stored at room temperature for longer than 4 hS Ramirez-Arcos, C Jenkins, W P Sheffield
Thrombosis Research|December 15, 1996
Inhibition of thrombin by hirudin genetically fused to wild-type or mutant antithrombinS Syed, K E Kelly, W P Sheffield
Blood|November 1, 1995
Intracellular events determine the fate of antithrombin UtahW P Sheffield, J E Castillo, M A Blajchman
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Current Drug Targets. Cardiovascular & Haematological Disorders|May 29, 2003
Modification of clearance of therapeutic and potentially therapeutic proteinsW P Sheffield
Thrombosis Research|August 1, 1994
Amino acid substitutions of the P2 residue of human antithrombin that either enhance or impair functionW P Sheffield, M A Blajchman
FEBS Letters|February 14, 1994
Site-directed mutagenesis of the P2 residue of human antithrombinW P Sheffield, M A Blajchman
FEBS Letters|May 29, 1995
Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpinW P Sheffield, M A Blajchman
Vox Sanguinis|July 17, 2015
Stability of coagulation protein activities in single units or pools of cryoprecipitate during storage at 20-24°C for up to 24 hW P Sheffield, V Bhakta, C Jenkins
The Journal of Biological Chemistry|December 5, 1989
Regulation of ornithine aminotransferase in retinoblastomasR J Fagan, W P Sheffield, R Rozen
Biochemical and Biophysical Research Communications|January 14, 1986
Expression in Escherichia coli of functional precursor to the rat liver mitochondrial enzyme, ornithine carbamyl transferase. Precursor import and processing in vitroW P Sheffield, M Nguyen, G C Shore
Vox Sanguinis|April 7, 2017
Bacteria can proliferate in thawed cryoprecipitate stored at room temperature for longer than 4 hS Ramirez-Arcos, C Jenkins, W P Sheffield
Thrombosis Research|December 15, 1996
Inhibition of thrombin by hirudin genetically fused to wild-type or mutant antithrombinS Syed, K E Kelly, W P Sheffield
Blood|November 1, 1995
Intracellular events determine the fate of antithrombin UtahW P Sheffield, J E Castillo, M A Blajchman
Pageof 4